Treatment and prophylaxis of haemorrhage in patients with haemophilia A or B with inhibitors to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann’s thrombasthenia.
Factor VIIa (recombinant)
Recombinant factor VIIa is a biosynthetic preparation of activated factor VII produced by recombinant DNA technology. It is a vitamin K-dependent glycoprotein. It promotes haemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor and may activate coagulation factor X and factor IX. Factor VIIa is given as the recombinant form, eptacog alfa (activated).
BY INTRAVENOUS INJECTION Adult: (consult haematologist).
Increased risk of thromboembolism with activated or non-activated prothrombin complex concentrate.
Disseminated intravascular coagulation . risk of thrombosis.
Uncommon Deep vein thrombosis . fever . pulmonary embolism . rash . venous thromboembolic events Rare Angina . arterial thrombotic events . cerebrovascular accident . coagulation disorders . headache . myocardial infarction . nausea Frequency not known Anaphylaxis . angioedema . flushing.
There are no controlled data in human pregnancy and lactation
Store between 2-25° C prior to reconstitution. Do not freeze. Protect from light.
.png&w=384&q=75)